Overview

Study Evaluating Safety, Tolerability and Efficacy of YM150 in Subjects With Acute Coronary Syndromes

Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of various doses of YM150 (the experimental drug) in the prevention of ischemic vascular events in subjects with recent acute coronary syndromes.
Phase:
Phase 2
Details
Lead Sponsor:
Astellas Pharma Europe B.V.
Treatments:
Darexaban